Glioblastoma

New insights for a therapeutic approach in glioblastoma

(PhysOrg.com) -- Scientists from the Friedrich Miescher Institute for Biomedical Research have identified a new and important molecular player in glioblastoma. The amount of the MNK1 kinase is not only dramatically increased ...

Mar 18, 2011
popularity0 comments 0

Custom-tailored strategy against glioblastomas

Glioblastomas are incurable malignant brain tumors. Usually the patients affected survive for only a few months. In addition, every tumor is quite different, which makes treatment very difficult. Researchers at the University ...

Sep 26, 2016
popularity2 comments 0

Innate immune landscape in glioblastoma patient tumors

Glioblastoma is an extremely aggressive brain tumor with limited treatment options. Recent progress in using immunotherapy-based treatment options in other tumor types has spurred interest in developing approaches that might ...

Feb 25, 2016
popularity0 comments 0

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Unlocking the heart-protective benefits of soy

A product of digesting a micronutrient found in soy may hold the key to why some people seem to derive a heart-protective benefit from eating soy foods, while others do not, a University of Pittsburgh Graduate School of Public ...

Using a rabbit virus to treat multiple myeloma

Treating multiple myeloma (MM) with myxoma virus (MYXV) eliminated a majority of malignant cells in preclinical studies, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in an article ...

T cells support long-lived antibody-producing cells

If you've ever wondered how a vaccine given decades ago can still protect against infection, you have your plasma cells to thank. Plasma cells are long-lived B cells that reside in the bone marrow and churn out antibodies ...